EA200500814A1 - Производные пирролопиримидина - Google Patents
Производные пирролопиримидинаInfo
- Publication number
- EA200500814A1 EA200500814A1 EA200500814A EA200500814A EA200500814A1 EA 200500814 A1 EA200500814 A1 EA 200500814A1 EA 200500814 A EA200500814 A EA 200500814A EA 200500814 A EA200500814 A EA 200500814A EA 200500814 A1 EA200500814 A1 EA 200500814A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- formula
- compounds
- relates
- pyrropolymidinine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Изобретение относится к соединениям формулы 1 или их фармацевтически приемлемой соли, пролекарству или гидратам, где Q, A, L, R, Rи Rявляются такими, как определено здесь. Изобретение также относится к фармацевтическим композициям, содержащим соединения формулы 1, и к способам лечения гиперпролиферативных расстройств у млекопитающего путем введения соединений формулы 1.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43456802P | 2002-12-19 | 2002-12-19 | |
PCT/IB2003/005841 WO2004056830A1 (en) | 2002-12-19 | 2003-12-08 | Pyrrolopyrimidine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200500814A1 true EA200500814A1 (ru) | 2006-02-24 |
Family
ID=32682064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500814A EA200500814A1 (ru) | 2002-12-19 | 2003-12-08 | Производные пирролопиримидина |
Country Status (34)
Country | Link |
---|---|
US (1) | US7271262B2 (ru) |
EP (1) | EP1578751B1 (ru) |
JP (1) | JP4057013B2 (ru) |
KR (2) | KR20070087020A (ru) |
CN (1) | CN1726218A (ru) |
AP (1) | AP2005003342A0 (ru) |
AR (1) | AR042509A1 (ru) |
AT (1) | ATE512965T1 (ru) |
AU (1) | AU2003286317A1 (ru) |
BR (1) | BR0317524A (ru) |
CA (1) | CA2510853C (ru) |
EA (1) | EA200500814A1 (ru) |
EC (1) | ECSP055867A (ru) |
ES (1) | ES2364649T3 (ru) |
GT (1) | GT200300289A (ru) |
HN (1) | HN2003000416A (ru) |
HR (1) | HRP20050560A2 (ru) |
IS (1) | IS7872A (ru) |
MA (1) | MA27568A1 (ru) |
MX (1) | MXPA05006793A (ru) |
NL (1) | NL1025068C2 (ru) |
NO (1) | NO20052802L (ru) |
NZ (1) | NZ540456A (ru) |
OA (1) | OA12976A (ru) |
PA (1) | PA8591701A1 (ru) |
PE (1) | PE20040914A1 (ru) |
PL (1) | PL377774A1 (ru) |
RS (1) | RS20050469A (ru) |
TN (1) | TNSN05165A1 (ru) |
TW (1) | TW200423939A (ru) |
UA (1) | UA80171C2 (ru) |
UY (1) | UY28132A1 (ru) |
WO (1) | WO2004056830A1 (ru) |
ZA (1) | ZA200504440B (ru) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1898240B (zh) * | 2003-10-15 | 2011-08-03 | Osi制药公司 | 咪唑并吡嗪类酪氨酸激酶抑制剂 |
WO2005047289A1 (en) * | 2003-11-17 | 2005-05-26 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
BRPI0509576A (pt) | 2004-04-02 | 2007-05-29 | Osi Pharm Inc | composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica |
WO2005116035A1 (en) * | 2004-05-27 | 2005-12-08 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
TW200613306A (en) * | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
PL1858877T3 (pl) | 2005-01-14 | 2014-08-29 | Gilead Connecticut Inc | 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy |
US20070287719A1 (en) * | 2005-03-11 | 2007-12-13 | Pfizer Inc | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea |
US7777040B2 (en) | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
US7795248B2 (en) * | 2005-05-18 | 2010-09-14 | Abbott Laboratories, Inc. | Substituted 7,8-dihydro-1H-pyrimido[4,5-B][1,4]diazepin-4-amines are novel kinase inhibitors |
DE102005037499A1 (de) * | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
WO2007024754A1 (en) * | 2005-08-22 | 2007-03-01 | Amgen Inc. | Bis-aryl urea compounds for the treatment of protein kinase-mediated diseaes |
US8592433B2 (en) * | 2005-10-28 | 2013-11-26 | Advait Nagle | Compounds and compositions as protein kinase inhibitors |
EP2385053B1 (en) * | 2005-11-17 | 2013-10-02 | OSI Pharmaceuticals, Inc. | Intermediates for the preparation of fused bicyclic mTOR inhibitors |
US20070135387A1 (en) * | 2005-12-08 | 2007-06-14 | Michaelides Michael R | Inhibitors of protein kinases |
WO2007066189A2 (en) * | 2005-12-09 | 2007-06-14 | Pfizer Products Inc. | Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea |
JP2009520028A (ja) * | 2005-12-19 | 2009-05-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Igfr抑制剤および抗癌剤の併用 |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
ES2545907T3 (es) * | 2005-12-29 | 2015-09-16 | Abbvie Inc. | Inhibidores de proteína quinasa |
ES2689444T3 (es) * | 2006-11-22 | 2018-11-14 | Incyte Holdings Corporation | Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008076143A1 (en) * | 2006-12-18 | 2008-06-26 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US20100331297A1 (en) * | 2007-11-07 | 2010-12-30 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
PE20091846A1 (es) * | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
AU2009257635A1 (en) * | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
WO2009152087A1 (en) * | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor |
AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
ES2570429T3 (es) * | 2008-10-16 | 2016-05-18 | Univ California | Inhibidores de heteroaril quinasa de anillo condensado |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
MY172424A (en) | 2009-04-03 | 2019-11-25 | Hoffmann La Roche | Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof |
CA2752826A1 (en) | 2009-04-20 | 2010-10-28 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
BR112012003462A2 (pt) | 2009-08-24 | 2016-02-23 | Ascepion Pharmaceuticals Inc | "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase." |
BR112012012156A2 (pt) | 2009-11-06 | 2015-09-08 | Plexxikon Inc | compostos e métodos para modulação de cinase, e indicações para esta |
ES2627911T3 (es) * | 2009-11-18 | 2017-08-01 | Plexxikon, Inc. | Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer |
US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
CN102892768A (zh) | 2009-12-30 | 2013-01-23 | 艾科尔公司 | 被取代的吡咯并氨基嘧啶化合物 |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
WO2012064744A2 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
TR201816421T4 (tr) | 2011-02-07 | 2018-11-21 | Plexxikon Inc | Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları. |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
UA108926C2 (ru) | 2011-04-05 | 2015-06-25 | Пфайзер Лімітед | LibreOffice? [2,3-D] +" +" !+ |
KR20140048968A (ko) * | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
WO2013032951A1 (en) | 2011-08-26 | 2013-03-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
JP6093768B2 (ja) | 2011-09-14 | 2017-03-08 | ニューファーマ, インコーポレイテッド | 特定の化学的実体、組成物、および方法 |
WO2013112950A2 (en) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
BR112014018450A8 (pt) * | 2012-01-25 | 2017-07-11 | Bayer Ip Gmbh | Fenilimidazopirazoles substituídos e sua utilização |
US9394315B2 (en) | 2012-05-08 | 2016-07-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US9657033B2 (en) | 2012-05-08 | 2017-05-23 | Lycera Corporation | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014047648A1 (en) | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
JP2015532287A (ja) | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ire1の調節 |
EP2903989A1 (en) | 2012-10-04 | 2015-08-12 | Pfizer Limited | Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors |
EP2903986A1 (en) | 2012-10-04 | 2015-08-12 | Pfizer Limited | Tropomyosin-related kinase inhibitors |
JP2015531395A (ja) | 2012-10-04 | 2015-11-02 | ファイザー・リミテッドPfizer Limited | ピロロ[3,2−c]ピリジントロポミオシン関連キナーゼ阻害剤 |
EP2916838B1 (en) | 2012-11-12 | 2019-03-13 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
CA2934010A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
CN106132422A (zh) | 2014-02-27 | 2016-11-16 | 莱斯拉公司 | 使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法&相关治疗方法 |
EP3131891A1 (en) | 2014-04-15 | 2017-02-22 | Pfizer Inc. | Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety |
EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
AU2015256190B2 (en) | 2014-05-05 | 2019-08-15 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
WO2015170218A1 (en) | 2014-05-07 | 2015-11-12 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
WO2016009296A1 (en) | 2014-07-16 | 2016-01-21 | Pfizer Inc. | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
WO2016020784A1 (en) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CN107108631B (zh) | 2014-11-14 | 2020-06-16 | 内尔维阿诺医学科学有限公司 | 作为蛋白激酶抑制剂的6-氨基-7-二环-7-脱氮-嘌呤衍生物 |
JP2018510135A (ja) | 2015-02-11 | 2018-04-12 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害剤としての置換ピラゾール化合物及びその使用 |
EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
JP6793401B2 (ja) * | 2015-03-11 | 2020-12-02 | 国立研究開発法人理化学研究所 | 難治性白血病治療薬 |
CA2982847A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
KR20180025894A (ko) | 2015-06-11 | 2018-03-09 | 라이세라 코퍼레이션 | Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료 |
MA41559A (fr) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
EP3368539B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as ror gamma t inhibitors and uses thereof |
WO2017075178A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
KR20180094940A (ko) * | 2015-12-02 | 2018-08-24 | 아스트레아 테라퓨틱스 엘엘씨 | 피페리디닐 노시셉틴 수용체 화합물 |
US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
WO2017133669A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | 5, 7-diazaindole and 5, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza |
PT3269370T (pt) | 2016-02-23 | 2020-03-05 | Taiho Pharmaceutical Co Ltd | Novo composto de pirimidina condensada ou sal do mesmo |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CN110461849B (zh) * | 2017-06-19 | 2020-09-01 | 上海和誉生物医药科技有限公司 | 一种csf1r抑制剂及其制备方法和应用 |
WO2019036001A1 (en) * | 2017-08-17 | 2019-02-21 | Vyera Pharmaceuticals, LLC | CDPK1 INHIBITOR, COMPOSITIONS AND RELATED METHODS |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CN112574200B (zh) | 2021-02-26 | 2021-06-11 | 安润医药科技(苏州)有限公司 | Btk和/或btk的突变体c481s的小分子抑制剂 |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB981458A (en) * | 1961-12-04 | 1965-01-27 | Wellcome Found | Pyrrolo[2,3-d]pyrimidines |
US4218374A (en) * | 1972-10-20 | 1980-08-19 | Fujisawa Pharmaceutical Company, Limited | Penam derivatives |
DE3145287A1 (de) * | 1981-11-14 | 1983-05-19 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
AU1794697A (en) * | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
WO1997034895A1 (de) * | 1996-03-15 | 1997-09-25 | Novartis Ag | NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
ID24653A (id) * | 1997-03-19 | 2000-07-27 | Basf Ag | Zat-zat terapi |
JP2002526500A (ja) | 1998-09-18 | 2002-08-20 | ビーエーエスエフ アクチェンゲゼルシャフト | プロテインキナーゼ阻害剤としてのピロロピリミジン |
TR200101395T2 (tr) * | 1998-09-18 | 2001-11-21 | Basf Ag. | Kinaz engelleyiciler olarak 4-Aminopyrrolopyrimidin'ler |
AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
EP2324825A1 (en) * | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
-
2003
- 2003-08-12 UA UAA200506094A patent/UA80171C2/uk unknown
- 2003-12-08 BR BR0317524-3A patent/BR0317524A/pt not_active IP Right Cessation
- 2003-12-08 OA OA1200500187A patent/OA12976A/en unknown
- 2003-12-08 ES ES03777060T patent/ES2364649T3/es not_active Expired - Lifetime
- 2003-12-08 KR KR1020077015815A patent/KR20070087020A/ko not_active Application Discontinuation
- 2003-12-08 RS YUP-2005/0469A patent/RS20050469A/sr unknown
- 2003-12-08 CN CNA2003801064513A patent/CN1726218A/zh active Pending
- 2003-12-08 NZ NZ540456A patent/NZ540456A/en unknown
- 2003-12-08 KR KR1020057011297A patent/KR20050084402A/ko not_active Application Discontinuation
- 2003-12-08 AT AT03777060T patent/ATE512965T1/de not_active IP Right Cessation
- 2003-12-08 WO PCT/IB2003/005841 patent/WO2004056830A1/en active Application Filing
- 2003-12-08 JP JP2004561818A patent/JP4057013B2/ja not_active Expired - Fee Related
- 2003-12-08 MX MXPA05006793A patent/MXPA05006793A/es not_active Application Discontinuation
- 2003-12-08 EP EP03777060A patent/EP1578751B1/en not_active Expired - Lifetime
- 2003-12-08 CA CA002510853A patent/CA2510853C/en not_active Expired - Fee Related
- 2003-12-08 AU AU2003286317A patent/AU2003286317A1/en not_active Abandoned
- 2003-12-08 PL PL377774A patent/PL377774A1/pl not_active Application Discontinuation
- 2003-12-08 EA EA200500814A patent/EA200500814A1/ru unknown
- 2003-12-08 AP AP2005003342A patent/AP2005003342A0/xx unknown
- 2003-12-10 US US10/732,509 patent/US7271262B2/en not_active Expired - Fee Related
- 2003-12-10 PA PA20038591701A patent/PA8591701A1/es unknown
- 2003-12-11 PE PE2003001266A patent/PE20040914A1/es not_active Application Discontinuation
- 2003-12-17 AR ARP030104681A patent/AR042509A1/es unknown
- 2003-12-17 UY UY28132A patent/UY28132A1/es not_active Application Discontinuation
- 2003-12-17 GT GT200300289A patent/GT200300289A/es unknown
- 2003-12-17 HN HN2003000416A patent/HN2003000416A/es unknown
- 2003-12-18 NL NL1025068A patent/NL1025068C2/nl not_active IP Right Cessation
- 2003-12-18 TW TW092135947A patent/TW200423939A/zh unknown
-
2005
- 2005-05-30 IS IS7872A patent/IS7872A/is unknown
- 2005-05-31 ZA ZA200504440A patent/ZA200504440B/en unknown
- 2005-06-09 NO NO20052802A patent/NO20052802L/no not_active Application Discontinuation
- 2005-06-16 HR HR20050560A patent/HRP20050560A2/hr not_active Application Discontinuation
- 2005-06-17 MA MA28346A patent/MA27568A1/fr unknown
- 2005-06-17 TN TNP2005000165A patent/TNSN05165A1/fr unknown
- 2005-06-17 EC EC2005005867A patent/ECSP055867A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200500814A1 (ru) | Производные пирролопиримидина | |
EA200600892A1 (ru) | Новые хинолиновые производные | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
ATE440603T1 (de) | 8-hydroxychinolinderivate | |
EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
EA200000391A1 (ru) | Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов | |
EA200200716A1 (ru) | Арилконденсированные азаполициклические соединения | |
EA200701745A1 (ru) | Циклопропанкарбоксамидные производные | |
EA200100135A1 (ru) | Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов | |
WO2006124692A3 (en) | 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same | |
WO2007138472A3 (en) | Triazolopyridazine derivatives | |
EA200870423A1 (ru) | Производные триазолпиразинов, применимые в качестве противораковых агентов | |
ATE309999T1 (de) | Blutplättchen-adp-rezeptor-inhibitoren | |
WO2006048750A3 (en) | Novel compounds of substituted and unsubstituted adamantyl amides | |
EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
ATE517882T1 (de) | Chinolinderivate | |
MXPA06002296A (es) | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. | |
EA200802058A1 (ru) | Производные циклоалкиламинокислот и их фармацевтические композиции | |
EA200401309A1 (ru) | Тризамещённые гетероарилы и способы их получения и применения | |
EA200870117A1 (ru) | Азаиндоловые ингибиторы аурора-киназ | |
EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
EA200801245A1 (ru) | [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними | |
TW200728307A (en) | Novel spirochromanone derivatives | |
EA200001146A1 (ru) | Производные изотиазола, применимые в качестве противораковых агентов |